Birmingham, ALNCT06969755Now EnrollingIRB Ready

Schizophenia Disorder Clinical Trial in Birmingham, AL

Access cutting-edge schizophenia disorder treatment through this phase 4 clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.

Sponsored by Northwell Health

Quick Self-Assessment

See if you qualify for this Birmingham location

Preparing your pre-screening questions…

Expert Care in Birmingham

Access schizophenia disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related schizophenia disorder treatment provided free

Apply for This Birmingham Location

Check if you qualify for this schizophenia disorder clinical trial in Birmingham, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Birmingham

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Birmingham site if eligible
  4. 4Begin participation

About This Schizophenia Disorder Study in Birmingham

This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.

Sponsor: Northwell Health

Who Can Participate

Inclusion Criteria

Aged 18 to 35.
DSM5 diagnosis (as determined by the SCID5) of schizophrenia, schizoaffective disorder, schizophreniform disorder.
Current positive symptoms rated ≥4 (moderate) on one or more of the following BPRS positive subscale items: unusual thought content, conceptual disorganization, hallucinatory behavior, suspiciousness.
Preserved striatal connectivity, as determined by screening MRI scan
Absence of the MC4R high-risk genotype, as determined by genetic testing
Absence of the HLA-DQB1 high-risk genotype, as determined by genetic testing
In an early phase of illness as defined by having taken antipsychotic drugs for a cumulative lifetime period of 4 weeks or less (with exceptions of very low doses for other off-label indications, e.g. sleep)
Ability to provide informed consent

Exclusion Criteria

The patient reports or medical records state a serious neurological or endocrine disorder at screening that the investigator determines could interfere with the interpretation of the efficacy or safety measurements
An abnormal EKG at screening that the investigator determines could interfere with the interpretation of the efficacy or safety measurements
Any medical condition which requires treatment with a medication with psychotropic effects.
Significant risk of suicidal or homicidal behavior (i.e. 'severe' risk on the Columbia Suicide Scale, a 'hostility' score of 7 on the BPRS, or an answer of 'yes' on questions 4,5 or 6 on the CDSS).
Cognitive limitations, or any other factor that would preclude potential participants providing informed consent
Contraindications to MRI (e.g. pacemaker).
Meeting SCID-5 substance use disorder moderate or severe for any substance, other than nicotine within 3 months of screening visit. Meeting SCID5 substance use disorder mild for any substance other than cannabis, alcohol, or nicotine for less than 3 months prior to screening visit, or a positive urine baseline drug screen with a substance other than nicotine, alcohol, or cannabis
Suspected DSM5 intellectual disability based upon clinical interview and psychosocial history, as well as screening with the Weschler Test for Adult Reading (IQ score \<71)
Prior psychosurgery
Pregnancy (self-report)
Seizure disorder (self-report) \-

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT06969755) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Schizophenia Disorder Treatment Options in Birmingham, AL

If you're searching for schizophenia disorder treatment options in Birmingham, AL, this clinical trial (NCT06969755) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced schizophenia disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all schizophenia disorder clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Hypertension Trials in Birmingham, AL

See all pulmonary hypertension clinical trials recruiting in Birmingham — not just this study.

Browse Pulmonary Hypertension Trials in Birmingham →

Browse More Trials by Condition

Pulmonary Hypertension TrialsAll Conditions →

Ready to Join in Birmingham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Birmingham, AL